HEALTHCARE
Florida seniors can now get GLP-1 weight-loss drugs for $50
But the temporary new benefit has some fine print Medicare recipients should know about
Anne GeggisUSA TODAY NETWORK – Florida
July 9, 2026, 5:02 a.m. ET
- A new Medicare program allows some beneficiaries to get popular GLP-1 weight-loss drugs for a $50 monthly co-pay.
- Previously, Medicare only covered these drugs for weight-related conditions like Type 2 diabetes or heart disease.
- To be eligible, patients must have Medicare drug coverage and meet specific body mass index (BMI) criteria.
- The “bridge” program is temporary, and its extension beyond 2027 would require a change in federal law.
Millions of Medicare beneficiaries could save tens of thousands a year as the Feds make a multibillion dollar bet that slimming elders’ waistlines could lighten the burden of Medicare’s costs — eventually
In a new twist, some Medicare beneficiaries can now get costly but popular GLP-1 drugs for $50 a month over the next 18 months if they are simply over a certain weight and enrolled in a Medicare plan that fits the bill. Before July 1, 2026, Medicare was prohibited from paying for weight loss management drugs
Previous to July 2026, Medicare covered these pricey GLP-1 prescriptions only if the beneficiary also had a weight-related condition such as Type 2 diabetes, sleep apnea, high blood pressure, and cardiovascular disease among other conditions
That $50 co-pay is more than $1,000 less than the typical, monthly out-of-pocket cost for the GLP-1 brand names that Medicare is covering: Wegovy, Zepbound or Foundayo
Dr. David Liporace, a board-certified internist who works in concierge medicine at Jupiter Medical Center, said he’s “very, very excited” about the difference the new coverage could make among Medicare beneficiaries
“If we can get that population healthier from the perspective that they are more lean and more active, then they will have less heart disease, they will have less kidney disease, they will have less dementia, which is huge, and they will fall less,” Liporace said, noting that GLP-1s have been shown to reduce dementia by 43% according to an analysis of multiple independent studies addressing the same research question. “We are going to have the opportunity to improve patient health, and therefore decrease costs.”
Not all studies are pointing in to overall reduced medical costs, however. And the temporary, new benefit has some fine print Medicare beneficiaries should know
Is Medicare going to pay for GLP-1 drugs in 2026?
What the feds are calling the Medicare GLP-1 Bridge program means that about 3.8 million Medicare beneficiaries could be eligible to get these drugs that have revolutionized weight loss in recent years for $50 a month, according to an analysis of 2023 Medicare data by KFF, a national health policy organization. The coverage was originally scheduled to expire at the end of 2026, but the “bridge” was extended to the end of 2027 months before it went into effect
Dr. Amy Sheer, who runs a weight management clinic at University of Florida Health, says she’s particularly glad to see the trial period extended — it would be hard to see the health or medical cost benefits from a six-month pilot
Usually, it takes several months for doctors to adjust the dosage to optimize effects and minimize side effects for each patient. Most patients need time to adapt to the medication that works by slowing down digestion and boosting the pancreas’ ability to produce insulin, experience with the drugs have shown. And much patient experience has found that quitting the drugs after being on them often causes patients’ weight and appetite to come roaring back
“Clinical trials are usually 52 to 72 weeks, depending on the trial and comorbidity (weight-related medical complication) so at least that gives us more time to get people to a good dose and a goal,” Sheer said
How do you get GLP-1 covered by Medicare?
Most Medicare beneficiaries can take advantage of the new benefit simply by going to their health care providers who will determine whether they meet the medical criteria for getting the medications for $50 a month, regardless of income. Providers will then submit the necessary prescription and prior authorization directly to the right pharmacies
But not every Medicare beneficiary is universally eligible, however. And the $50-a-month cost to the program can’t be counted as part of the beneficiaries’ deductible to trigger prescription benefits
Also, those in line to get the new benefit must meet all the following specific criteria, according to a Medicare fact sheet. Eligible patients must:
- Have Medicare Part D coverage, either through a standalone Medicare drug plan or a Medicare Advantage plan that includes drug coverage. Beneficiaries with special plan types, like the private, fee-for-service plans or contract plans, are not eligible.
- Not be eligible for GLP-1 drug coverage through the current plan chosen during the latest sign-up. Those who were getting the drugs through their current plan because of a weight-related condition, for example, must keep getting their GLP-1 drugs that way.
- Are at least 18 years of age and meet a certain body mass index (BMI) or higher.
- If your BMI, according to this calculator, is lower than 35, which would be 204 pounds at 5 feet, 4 inches or 237 pounds at 5 feet, 9 inches, you must also have an attendant medical condition to qualify for the new benefit.
What happens after the GLP-1 ‘bridge’ program ends?
After the $50-a-month GLP-1 program ends in 2027, Congress would have to change the federal law that prohibits Medicare from covering drugs for weight loss alone
It’s a developing situation — as the savings for paying for the drugs is not yet obvious on a systemwide basis
Part of the jump in insurance costs that occurred in 2026 has been blamed on how insurance companies have been shouldering more costs as more enrollees have utilized these new, expensive drugs
The Congressional Budget Office (CBO) in 2024 put out an analysis that found extending the coverage of GLP-1s to Medicare beneficiaries classified as “overweight” — a BMI of 25 or higher (or 5’4” and a weight of 145 or more) would cost the federal government $35 billion from 2026 to 2034
It might be a tough pill to swallow, considering how Medicare’s ability to continue its current funding is facing degradation in 2033, if nothing is done to change its current funding mechanisms
Still, the CBO projects that $50 million in medical expenses the drugs could have saved had it been in place throughout 2026 would rise to $1 billion in 2034
UF’s Sheer, also a UF College of Medicine professor who is the program director for the Obesity Medicine Fellowship at UF Health, was part of a research team that published a study in the Journal of the American Medical Heart Association, showing that patients with auto-immune diseases who took GLP-1s had fewer life-threatening blood clot blockages, lower emergency department use, and decreased mortality
The design of the study was not the same rigor as a randomized drug trial, but Sheer said she believes that Medicare’s new benefit will encourage more insurance companies to see how offering GLP-1 coverage to lose weight benefits insurance companies’ bottom line, despite the cost of the drugs
It’s a fierce debate, however. A 2025 University of Chicago found that although GLP-1s deliver impressive long-health improvements, “their current prices far exceed accepted thresholds for cost -effectiveness, posing difficult choices for policymakers, insurers and patients,” a report on the study reads
The conflicting data doesn’t surprise Sheer
“It’s a hard thing to capture, especially since it depends on how sick people are at baseline,” Sheer said
Are there special concerns for seniors taking GLP-1s?
GLP-1 prescriptions have quadrupled since taking them for weight loss specifically started in 2021 with the Food and Drug Administration’s approval of Wegovy for chronic weight loss management
Weight loss as dramatic as these drugs can trigger should be monitored, UF’s Sheer says. And the drugs’ side effects, like stomach upset, may require professional support, she said
Jupiter Medical Center’s Liporace said that GLP-1s can result in bone and muscle loss for adults of any age — and could aggravate the natural loss that happens in advanced years also
“We can’t always control when we are losing weight as to whether we’re losing fat or muscle, and muscle loss in the elderly is very concerning and because it creates all sorts of potential health problems with bone loss and decreased functionality, and we never want to see that happen as people get older.” Liporace said
His patients are going to hear recommendations to exercise and take supplements, like vitamin D, on a regular basis
“We want to increase their (elders’) functionality, not decrease it,” Liporace said
To find out what kind of plan you have, visit Medicare.gov or call ll 1-800-MEDICARE (1-800-633-4227) to have a representative pull up your exact plan information
Anne Geggis is statewide reporter for the USA TODAY NETWORK FLORIDA, reporting on health and senior issues. If you have news tips, please send them to ageggis@usatodayco.com. You can get all of Florida’s best content directly in your inbox each weekday by signing up for the free newsletter, Florida TODAY, at https://palmbeachpost.com/newsletters
